# A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer

> **NCT00191984** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 46 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** irinotecan

## Key facts

- **NCT ID:** NCT00191984
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2007-02
- **Final completion:** 2008-05
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2011-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191984, "A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00191984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*